Global Precision Medicine Market, by Technology (Bioinformatics, Gene Sequencing, Drug Discovery, Precision Molecular Diagnostics, and Big Data Analytics), by Application (Oncology (Breast Cancer, Lung Cancer, and Others), Central Nervous System, Hematology, Respiratory, Immunology, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 73,946.2 Million in 2022 and is expected to exhibit a CAGR of 10.3% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Increased adoption of inorganic strategies such as partnerships and collaborations by the key players in the market is expected to drive growth of the global precision medicine market over the forecast period. For instance, in May 2019, Amgen Inc., a biopharmaceutical company, entered into a partnership with Syapse, Inc., a company powering precision medicine insights through its global provider network, announced a precision medicine collaboration in oncology. As a part of this agreement, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology.

Global Precision Medicine Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been significantly impacted significantly by the COVID-19 pandemic.

However, the COVID-19 pandemic caused the healthcare system to change and understand the potential benefits of precision medicine, thereby prompting researchers to research more about the advantages provided by them. The COVID-19 infection is highly variable, ranging from asymptomatic infections to severe, life-threatening manifestations. Personalized or precision medicine can play an important role in understanding individual susceptibility to infection as well as inter-individual variability in clinical course, prognosis, and response to treatment. Including personalized medicine into clinical practice can transform health care by enabling the design of preventive and therapeutic strategies for individual profiles, improving the detection of outbreaks, or defining transmission patterns at an increasingly local level. Researchers are carrying out further research on COVID-19 infection and precision medicines as a treatment option, which is expected to drive the market growth. For instance, in June 2020, the San Antonio Partnership for Precision Therapeutics (SAPP), an organization formed to maximize therapy effectiveness, announced the funding of three collaborative COVID-19 research efforts in San Antonio. Thus, due to the increasing research on precision medicine, the COVID-19 pandemic is expected to drive the global precision market growth over the forecast period.

Browse 27 Market Data Tables and 31 Figures spread through 156 Pages and in-depth TOC on “Global Precision Medicine Market”-  Forecast to 2028, Global Precision Medicine Market, by Technology (Bioinformatics, Gene Sequencing, Drug Discovery, Precision Molecular Diagnostics, and Big Data Analytics), by Application (Oncology (Breast Cancer, Lung Cancer, and Others), Central Nervous System, Hematology, Respiratory, Immunology, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/precision-medicine-market-145

Moreover, the increasing grants and funds to advance precision medicine research are expected to drive growth of the global precision medicine market over the forecast period. For instance, in October 2019, the National Institutes of Health (NIH), a medical research agency, awarded a US$ 3.7 million grant to Washington University School of Medicine, a leader in improving human health, to fund an open-source database that will aim to boost precision medicine and genomic research for cancer.

Key Takeaways of the Global Precision Medicine Market:

  • The global precision medicine market is expected to exhibit a CAGR of 10.3% during the forecast period due to the increasing launches of digital platforms that will enable to accelerate the development of precision medicines. For instance, in October 2020, Diaceutics PLC, a company working on precision medicines, announced the launch of DXRX, the diagnostic network which has been designed to accelerate the end-to-end development and commercialization of precision medicine diagnostics.
  • Among technology, the bioinformatics segment is estimated to hold a dominant position in the global precision medicine market over the forecast period, owing to the increased service launches. For instance, in August 2020, M2Gen, an oncology-focused health informatics solutions company announced the launch of its oncology-focused Bioinformatics Support Services. The company’s end-to-end bioinformatics solutions and pipelines are used for large-scale oncology studies that allow researchers in academic and pharmaceutical research globally to gain the most meaningful molecular insights in oncology.
  • Among regions, North America is estimated to account for the largest market share in the global precision medicine market over the forecast period, owing to the increasing awareness and developments in the field of precision medicine in the region. For instance, in June 2018, Genome Canada, a non-profit organization that aims to use genomics-based technologies, launched a national initiative to promote the clinical implementation of precision medicine. The launch of this strategy is a major step towards implementing precision health into Canada’s health-care system.
  • Major players operating in the global precision medicine market include Intomics, GENinCode, NanoString, Tepnel Pharma Services Limited, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc, QIAGEN, Quest Diagnostics Incorporated, Medtronic, Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, bioMérieux SA, F. Hoffmann-La Roche Ltd, Eli Lilly & Company, GlaxoSmithKline plc, Cepheid, AstraZeneca PLC, Myriad Genetics, Inc., Bristol-Myers Squibb Company, And Foundation Medicine, Inc.

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo